Obesity pipeline bulging nicely, says report

A report has found that the obesity pipeline is robust and containing a high level of diversity in both molecule types and molecular targets, despite the market’s clinical and regulatory challenges.

The GlobalData report, entitled Obesity: Gut Hormone Receptors Retain Commercial Prominence, states that 41% of products in the obesity pipeline are first-in-class—an indicator of a highly innovative therapy area.

Gut hormones have attracted interest in obesity research, following the success of bariatric surgery demonstrating sustained weight loss, which is suggested to contribute to the declining secretion of appetite-associated gut hormones by a number of studies. This supports the rationale of targeting gut hormones in obesity.